Cardiovascular Systems Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems


Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).

Built on the proven Diamondback 360® Orbital Atherectomy platform, the 2.00 Max Crown is uniquely designed to enable simultaneous modification of both intimal and medial calcium. The new 2.00 Max Crown features an increased 70-micron diamond coated crown that creates more efficient engagement in mixed plaque, helping to achieve optimal luminal gain in mild to moderately calcified lesions above the knee.

Dr. Amit Srivastava, MD, FACC, FABVM at Bay Area Heart Center in St. Petersburg, Fla., was one of the first physicians in the U.S. to incorporate the 2.00 Max Crown into his practice.

Said Dr. Srivastava, “The new 2.00 Max Crown greatly expands the lesions that can be treated with CSI’s Orbital Atherectomy. This device delivers exceptional luminal gain in mixed morphology lesions above the knee.”

Scott R. Ward, Chairman, President and Chief Executive Officer of CSI, said, “The full commercial launch of the 2.00 Max Crown represents another important product launch for CSI as we broaden and diversify our product offering. Our peripheral orbital atherectomy systems can now treat a wider range of plaque morphologies throughout the leg. Combining this new device with our full line of interventional support devices, we continue to advance the ability of physicians to improve outcomes for patients undergoing peripheral interventions.”

About Peripheral Artery Disease (PAD)
Eighteen to 20 million Americans, most over age 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.